Business Context and Reporting Period
Company: Maravai LifeSciences Holdings, Inc. (MRVI)
Filing Type: Form 8-K (Current Report)
Date: March 20, 2025
Context: This filing serves as a Regulation FD disclosure regarding financial guidance for the full fiscal year 2025 and the first quarter of 2025, presented during a financial results conference call.
Key Financial Metrics and Guidance
The filing provides forward-looking guidance for 2025 based on existing business operations, excluding potential new acquisitions or unidentified items.
| Metric | Guidance Range / Value |
|---|---|
| Full Year 2025 Revenue | $185.0 million to $205.0 million |
| Q1 2025 Revenue | $43.0 million to $45.0 million |
| Interest Expense (Net) | $14.0 million to $16.0 million |
| Depreciation and Amortization | $50.0 million to $55.0 million |
| Stock-Based Compensation | $45.0 million to $50.0 million |
| Capital Expenditures | $15.0 million to $20.0 million |
| Diluted Shares Outstanding | Approximately 256 million (as-if fully converted) |
Note: The filing does not provide specific guidance for net profit, cash flow, or margins, only the components excluded from Adjusted EBITDA calculations.
Material Changes and Outlook
This filing does not report historical financial results or material changes compared to prior periods. Instead, it outlines management's expectations for the upcoming fiscal year. The guidance explicitly excludes the financial impact of potential new acquisitions or items not yet identified or quantified.
Risks and Contingencies
- Forward-Looking Nature: All guidance is subject to inherent uncertainties, risks, and changes in circumstances outside of management's control.
- Exclusions: Projections do not account for potential new acquisitions or unidentified items.
- Legal Disclaimer: The information in Item 7.01 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Reference to Risk Factors: Investors are directed to the "Risk Factors" and "Management's Discussion and Analysis" sections of the most recent Form 10-K and 10-Q for a detailed list of factors that could cause actual results to differ materially.
Investor Verification Checklist
- Verify the actual Q1 2025 revenue against the $43.0M - $45.0M guidance range once the 10-Q is filed.
- Review the most recent Form 10-K and 10-Q for detailed "Risk Factors" referenced in this 8-K.
- Monitor for any announcements regarding new acquisitions, as the current guidance explicitly excludes their financial impact.
- Confirm the final diluted share count of 256 million in subsequent quarterly filings.